James Andrew Jamison

US Patent:

6670324, Dec 30, 2003

Filed:

Aug 30, 2001

Appl. No.:

09/943901

Inventors:

James A. Jamison - Indianapolis IN
Michael J. Rodriguez - Indianapolis IN
Venkatraghavan Vasudevan - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3800

US Classification:

514 7

Abstract:

The present invention relates to compounds of formula I: where R is a sugar moiety. The compounds are useful in inhibiting fungal and parasitic activity and infections.

US Patent:

7326731, Feb 5, 2008

Filed:

Sep 9, 2002

Appl. No.:

10/488519

Inventors:

Jennifer Rebecca Allen - Indianapolis IN, US
Stephen Andrew Hitchcock - Carmel IN, US
James Andrew Jamison - Indianapolis IN, US
Bin Liu - Fishers IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31/16
C07C 233/00

US Classification:

514613, 564161

Abstract:

The present invention relates to compounds of Formula I: Formula I which are agonists of the M-1 muscarinic receptor.

US Patent:

8507555, Aug 13, 2013

Filed:

Jun 15, 2007

Appl. No.:

12/305182

Inventors:

Thomas M. Miller - El Cajon CA, US
James M. Jamison - Stow OH, US

Assignee:

Summa Health System - Akron OH

International Classification:

A01N 43/08
A01N 35/00
A61K 31/34

US Classification:

514474, 514681

Abstract:

Compositions comprising combinations of magnesium ascorbate (magnesium Vitamin C of “MgVC”) and Vitamin K3 or (VK3) or a quinone and semiquinone analogue of VK3, are used in methods for killing or inhibiting the growth of tumor or cancer cells or preneoplastic cells in a subject, or for treating cancer in a subject in need of such treatment.

US Patent:

56187874, Apr 8, 1997

Filed:

Mar 8, 1996

Appl. No.:

8/612520

Inventors:

James A. Jamison - Indianapolis IN
Michael J. Rodriguez - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3812
C07K 500

US Classification:

514 11

Abstract:

Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I ##STR1## wherein: R', R", R'", R. sup. x1, R. sup. x2, R. sup. y1, R. sup. y2, R. sup. y3, R. sup. y4 and R. sup. 0 are as defined hereinabove; and R. sup. 2 is ##STR2## R. sup. 3 is ##STR3## R. sup. 3a, R. sup. 3b, R. sup. 3c and R. sup. 3d are independently hydrogen, C. sub. 1 -C. sub. 12 alkyl, C. sub. 2 -C. sub. 12 alkynyl, C. sub. 1 -C. sub. 12 alkoxy, C. sub. 1 -C. sub. 12 alkylthio, halo, or --O--(CH. sub. 2). sub. m --[O--(CH. sub. 2). sub. n ]. sub. p --O--(C. sub. 1 -C. sub. 12 alkyl) or --O--(CH. sub. 2). sub. q --X--R. sup. 4 ; m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; q is 2, 3 or 4; X is pyrrolidino, piperidino or piperazino; and R. sup. 4 is hydrogen, C. sub. 1 -C. sub. 12 alkyl, C. sub. 3 -C. sub.

US Patent:

56522134, Jul 29, 1997

Filed:

Mar 11, 1996

Appl. No.:

8/613949

Inventors:

James A. Jamison - Indianapolis IN
Michael J. Rodriguez - Indianapolis IN
Lisa M. H. LaGrandeur - Tucson AZ
William W. Turner - Bloomington IN
Mark J. Zweifel - Indianapolis IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07K 14755
C07K 756
C07K 764

US Classification:

514 11

Abstract:

Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I: ##STR1## wherein R', R", R. sup. x1, R. sup. x2, R. sup. y1 -R. sup. y4, R. sup. z1, R. sup. z2, a, b, c, d, e, R. sup. 0, R. sup. 1 and R. sup. 2 are defined as in the specification.

US Patent:

56461119, Jul 8, 1997

Filed:

Mar 7, 1996

Appl. No.:

8/612208

Inventors:

Peter S. Borromeo - Fishers IN
James A. Jamison - Indianapolis IN
Michael J. Rodriguez - Indianapolis IN
William W. Turner - Bloomington IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07K 764
C07K 750

US Classification:

514 11

Abstract:

Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I: ##STR1## wherein: R' is hydrogen, methyl or NH. sub. 2 C(O)CH. sub. 2 --; R" and R'" are independently methyl or hydrogen; R. sup. x1, R. sup. x2, R. sup. y1, R. sup. y2, R. sup. y3, and R. sup. y4 are independently hydroxy or hydrogen; R. sub. 0 is a group of the formula ##STR2## R. sub. 1 is C. sub. 1 -C. sub. 6 alkyl, C. sub. 1 -C. sub. 6 alkoxy, phenyl, p-halo-phenyl, p-nitrophenyl, phenoxy, benzyl, p-halo-benzyl, or p-nitro-benzyl; and R. sub. 2 is an acyl side chain as defined herein.

US Patent:

6323176, Nov 27, 2001

Filed:

Feb 5, 1999

Appl. No.:

9/245572

Inventors:

James Andrew Jamison - Indianapolis IN
Michael John Rodriguez - Indianapolis IN
Venkatraghavan Vasudevan - Indianapolis IN

Assignee:

Eli Lilly and Company

International Classification:

A61K 3800
A61K 3812
C07K 700
C07K 756

US Classification:

514 7

Abstract:

The present invention relates to compounds of formula ##STR1## where R. sup. 5 is a sugar moiety. The compounds are useful in inhibiting fungal and parasitic activity and infections.

US Patent:

20220306680, Sep 29, 2022

Filed:

Mar 22, 2022

Appl. No.:

17/700910

Inventors:

- Indianapolis IN, US
Jacqueline Mary WURST - Indianapolis IN, US
James Andrew JAMISON - La Jolla CA, US

International Classification:

C07J 17/00
A61P 17/00

Abstract:

The present invention provides a compound of Formula I:wherein R is hydrogen, —P(═O)(OH),or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and inflammatory bowel disease.